Genitourinary Cancers

• Anticancer therapy at the end of life of breast, prostate, and colorectal cancer patients
• EXTEND: Safety and efficacy of exercise training in men <break/>receiving enzalutamide (ENZ) in combination with conventional androgen deprivation...
• High proportion of prostate cancer survivors continue to <break/>experience a negative impact on quality of life long after diagnosis: Patient repo...
• Patients&#x02019; and partners&#x02019; views of treatment and care provided for metastatic castrate resistant prostate cancer (mCRPC) in the UK
• A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant pr...
• Relationship between apalutamide (APA) exposure and metastasis-free survival (MFS) in patients (pts) with nonmetastatic castration-resistant prosta...
• Prolonged urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide: Res...
• Abiraterone acetate plus prednisone and LHRH therapy versus abiraterone acetate plus prednisone while sparing LHRH therapy in patients with progres...
• Association of grade &#x02265;3 neutropenia (NP) with outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving c...
• Post hoc responder analysis of health&#x02010;related quality of life (HRQL) in patients with metastatic castration&#x02010;resistant prostate canc...
• Comparative efficacy and cost-effectiveness of maximum androgen blockade (MAB), docetaxel with androgen deprivation therapy (ADT), and ADT alone fo...
• Randomized trial of androgen deprivation therapy (ADT) &#x0002B; enzalutamide (Arm A) versus ADT &#x0002B; bicalutamide (Arm B) in metastatic hormo...
• Health-related quality of life (HRQoL) after progressive disease (PD) in SPARTAN: A phase III trial of apalutamide (APA) versus placebo (PBO) in me...
• The prognostic value of the proportion and subtype patterns of intraductal carcinoma of the prostate in patients with <italic>de novo</italic> meta...
• Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation th...
• Non-metastatic castration-resistant prostate cancer (nmCRPC): Meta-analysis of efficacy and safety with novel hormonal agents apalutamide and enzal...
• Statin use and outcome in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated in the TROPIC trial
• Use of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) af...
• Clinical outcome with radium-223 (Ra-223) in patients (pts) previously treated with abiraterone (Abi) or enzalutamide (Enza): A retrospective study...
• Symptomatic skeletal event (SSE) dynamics in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (R...
• Post hoc analysis of the effect of baseline characteristics on treatment duration in patients with metastatic castration-resistant prostate cancer...
• Prognostic associations of early prostate-specific antigen (PSA) changes in patients with metastatic castration-resistant prostate cancer treated w...
• Cabazitaxel under routine conditions for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC): Interim results of...
• Efficacy of therapies after progression to up-front docetaxel (D) with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate...
• Radium-223 (Ra-223) therapy after abiraterone (Abi): Analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP)...

• « Previous
• 1
• 2
• ...
• 79
• Next »